Around half of those hospitalised with COVID-19 and who show raised levels of a protein called troponin have suffered some damage to their heart, according to a new study which included patients at the Royal Free London.
Patients from the Royal Free London are among those who took part in the study which looked at the impact of raised levels of troponin on the heart in those who had been in hospital with COVID-19.
The study showed around 50% of patients who have been hospitalised with COVID-19 and who show raised levels of troponin had some injury to their hearts. The injury was detected by a magnetic resonance imaging (MRI) scan at least a month after discharge, according to new findings published today in the European Heart Journal.
Heart injury includes inflammation of the heart muscle (myocarditis), scarring or death of heart tissue (infarction), restricted blood supply to the heart (ischaemia) and combinations of all three.
The study of 148 patients from the Royal Free London and five other acute hospitals in London is the largest study to date to investigate convalescing COVID-19 patients who had raised troponin levels, indicating a possible problem with the heart.
Troponin is released into the blood when the heart muscle is injured. Raised levels can occur when an artery becomes blocked or there is inflammation of the heart. Many patients who are hospitalised with COVID-19 have raised troponin levels during the critical illness phase, when the body mounts an exaggerated immune response to the infection. Troponin levels were elevated in all the patients in this study. Those patients were then followed up with MRI scans of the heart after discharge in order to understand the causes and extent of the damage.
Professor Marianna Fontana (pictured), director of the UCL cardiac magnetic resonance unit at the Royal Free Hospital, who led the research, said: “Raised troponin levels are associated with worse outcomes in COVID-19 patients. Patients with severe COVID-19 disease often have pre-existing heart-related health problems including diabetes, raised blood pressure and obesity. During severe COVID-19 infection, however, the heart may also be directly affected. Unpicking how the heart can become damaged is difficult, but MRI scans of the heart can identify different patterns of injury, which may enable us to make more accurate diagnoses and to target treatments more effectively.”
The researchers investigated COVID-19 patients discharged up until June 2020. Patients who had abnormal troponin levels were offered an MRI scan of the heart after discharge and were compared with those from a control group of patients who had not had COVID-19, as well as from 40 healthy volunteers.
The recovering COVID-19 patients had been very ill; all required hospitalisation and all had troponin elevation, with around one in three having been on a ventilator in the intensive care unit.
Prof. Fontana added: “We found evidence of high rates of heart muscle injury that could be seen on the scans a month or two after discharge. Whilst some of this may have been pre-existing, MRI scanning shows that some were new and likely caused by COVID-19. The pattern of damage to the heart was variable, suggesting that the heart is at risk of different types of injury. Importantly, we detected only a small amount of ongoing injury, with the heart’s pumping function being normal in most cases. In the most severe cases (small proportion), there are concerns that this injury may increase the risks of heart failure in the future, but more work is needed to investigate this further.
“These findings give us two opportunities: firstly, to find ways of preventing the injury in the first place, and from some of the patterns we have seen, blood clotting may be playing a role, for which we have potential treatments. Secondly, detecting the consequences of injury during convalescence may identify subjects who would benefit from specific supporting drug treatments to protect heart function over time.”
The findings of the study are limited by the nature of patient selection and included only those who survived coronavirus infection requiring hospital admission.
“The convalescent patients in this study had severe COVID-19 disease and our results say nothing about what happens to people who are not hospitalised with COVID, or those who are hospitalised but without elevated troponin. The findings indicate potential ways to identify patients at higher or lower risk and suggest potential strategies that may improve outcomes. More work is needed, and MRI scans of the heart have shown how useful it is in investigating patients with troponin elevation,” concluded Prof. Fontana.